Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07331272 | A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM) | PHASE1 | RECRUITING | 38 | — | — | Jan 29, 2026 | Jan 31, 2030 | Feb 2, 2026 | 5 | China |
| Arm | Type | Description |
|---|---|---|
| Chimeric antigen receptor T cells (LUCAR-G79D) | EXPERIMENTAL | Each subject will be given a single-dose LUCAR-G79D cells infusion at each dose level. |
| Name | Type | Description |
|---|---|---|
| LUCAR-G79D T cells | BIOLOGICAL | Prior to infusion of the LUCAR-G79D T cells, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine. |
Inclusion Criteria: 1. Subjects voluntary agreement to provide written informed consent. 2. Aged 18 to 70 years, either sex. 3. Adequate organ function meet screening criteria. 4. Positive test for cluster of differentiation antigen 19 (CD19). SLE: * Have been diagnosed of SLE at least 6 months b...